Just doesn't make sense - he's majority shareholder. He only steps down if he thinks it's in the best interests of the company, long-term. Anything else is pure imagination.
I think you nailed it. Look at how low the volume has been - this isn't some kind of massive bad news selloff. There is a lot of technical support in this area, right around 100 day moving average. If we can't hold here then the next line in the sand should be in the low $7 range.
Right, they are still majority owners which is why I was referring to "deliberate" insider selling in my posting on Jan. 31st. These automatic divestitures are intended to increase liquidity and help SCMP act more like a publicly traded company should. It often seems to cause short-term pain since investors get scared by insider selling, but in the long run it will allow for more serious interest from Wall Street.
SCMP is one of the safest plays in biotech. If there is a REAL market downturn, those other hype biotechs will be obliterated. With the recent selloff, SCMP now trades below 20 P/E and below 4 P/S which is ridiculously low considering three of the biggest holdings in the IBB (CELG, GILD, and BIIB) have P/E ratios over 40 and P/S over 10. The recent SP weakness has more to do with deliberate insider selling and general market weakness. Remember, volume is still very low for SCMP so big swings are common. Upcoming earnings report should provide a nice upward catalyst and reward longs.
It's starting to get serious when even Motley Fool starts noticing and praising SCMP.
Yeah, I hear what you're saying. As long as I've been on this board I've thought you had productive things to say about SCMP.
So I've looked into SGYP a bit, I just think it's overpriced from a risk/reward with a market cap north of $500M. Obviously, potential is high with a stock like that, but the floor is basically zero. I can't see pricing in success like that when there is so much that can go wrong in this complicated world of biotech. With SCMP you get the security provided by an already successful drug plus the potential of a deep pipeline, all for a market cap 2/3 the size of SGYP.
I wouldn't be opposed to trading SGYP in the right situation, though I'd prefer to play a stock like that through options.
In the meantime, stay long SCMP.
It's getting a bit ridiculous the last few days. Let's get back to constructive analysis, positive or negative - there are always going to be idiots on every board but just put them on ignore - like dealing with a child - don't feed into their tantrums.
Can't wait for next quarter results - expecting strong sales of Amitiza in Japan again which should further improve EPS; also expect the positive results for LSS indication to continue to boost SP - large and underserved market there.
Meh, that's pretty normal volume for SCMP, especially given light trading during holiday weeks - means nothing.
This is the main problem with most biotech investors. They completely ignore actual products and focus solely on "potential;" talking about SGYP beating out SCMP/Amitiza is so premature it's laughable. The fact is SCMP already has a successful drug in Amitiza and the market just continues to grow. As for SGYP, let's just say "there's many a slip twixt the cup and the lip."
Well I'm glad to hear you're long SCMP and I'm sure you are too. I wouldn't get hung up on daily fluctuations. The sky is the limit for this company.
Or maybe he do understand but just made the mistake of shorting SCMP.